We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Collaboration to Develop Diagnostic Tests for Breast Cancer

By HospiMedica staff writers
Posted on 26 Mar 2004
A research collaboration for the discovery and development of in vitro diagnostic tests for the early detection of breast cancer has been announced by Abbott Laboratories (Abbott Park, IL, USA) and Europroteome AG (Henningsdorf, Germany). More...


The collaboration will seek to identify novel markers for breast cancer diagnosis and potential screening and to develop tests for use on Abbott's automated instrument systems. Under the agreement, Europroteome will apply advanced proteomic and bioinformatic technologies to analyze serum samples from women with breast
cancer. Data will be aligned with a panel of cancer markers from Abbott. Combinations of markers will be selected for further development and integration into Abbott's instrument platforms, used widely in hospitals and clinical laboratories throughout the world.

Abbott will make upfront and milestone payments to Europroteome and
provide commercial assays and instruments. Abbott will have an option for a royalty-bearing license to the results from the research collaboration and will be responsible for commercial assay development and worldwide sales and marketing.

"We believe this collaboration will further enhance our ability to
develop important diagnostic tools for the early detection of breast cancer, which is key to successful treatment intervention,” said Edward L. Michael, president, Abbott Molecular Diagnostics. "We are impressed by Europroteome's approach to integrate diagnostic industry platform requirements into the discovery strategy.”


Europroteome is a product-focused biopharmaceutical company with an
associated network of oncology experts. The firm operates a state-of-the-art proteomics and gene-expression laboratory in Berlin-Hennigsdorf, Germany. Europroteome's mission is to advance the development of cancer drugs and diagnostics based on a unique discovery and validation process that merges both molecular and clinical data. Europroteome founded and operates the Clinical Cancer Network (CCN), which is one of the largest, best-organized and most interactive networks of its kind. The CCN currently consists of
experts from about 20 European institutions and is a unique source of medical and scientific know-how.




Related Links:
Abbott
Europroteome

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Infant Resuscitator
Easypuff
Newborn Hearing Screener
ALGO 7i
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.